April 2013 Issue of MMM
APRIL 2013 issue
The fact that Pfizer cut DTC spend by 30% and kept the top spot tells its own story
Consumer ad spend plunged in 2012, as the ranks of mass-market blockbusters thinned and marketers turned from TV toward digital. But the DTC debate rages ...
The days of 350-million-dollar TV spending may be gone, but top DTC campaigns must still be tied to unique insights. And, as Deborah Dick-Rath finds, ...
Social, mobile or cloud-based technologies may take some getting used to for clinical investigators. But the need to trim the time and cost of R&D ...
With two drugs for one ultra-orphan disease—Kynamro and Juxtapid—getting FDA's nod a month apart, intense competition is in the cards. Tanya Lewis looks at their ...
Kevin Rigby, VP/US country head of public affairs, Novartis Pharmaceuticals
As specialty drugs enter the respiratory market, alongside successors to current blockbusters, Noah Pines looks at how big pharma aspires to sustain sales, and how ...
"External drivers" can have a significant impact on determining the answer to your marketing question
The media's hyperbolic reaction to an FDA warning on Zithromax manages to both unduly frighten patients and skirt the real problem—the overuse of antibiotics
With sequester cuts taking effect at FDA and no sign of a deal to end them in sight, it's certain the approvals process will slow ...
A panel at the New York ePharma Summit discussed the split between doctors' needs and pharma's agenda
A study finds that many medical students and residents feel confident that they can accept gifts from the pharmaceutical industry and remain unbiased—although they aren't ...
News on Mylan, Royalty Pharma and Roche
Med Ed Report
ProPublica's Dollars for Docs database shows many firms continue to utilize physician speakers for non-CME product-related talks and consulting.
Although a popular part of the mix for some brands, meetings drew fewer dollars from pharma's coffers last year, according to research.
A panel following up on an anonymous complaint to UK industry self-policing arm PCMPA ruled for Roche in a case alleging inappropriate behavior at an ...
News on Pri-Med, Exhibitor magazine, Boehringer Ingelheim, QPharma and Elsevier
Members of newly formed American Association of Nurse Pracitioners will receive the journals of both groups that merged to form it
Medical publisher and news source JAMA Network's latest launch—the JAMA Network Reader—is finding new ways to engage readers and advertisers
News on Wiley, Journal of the Academy of Nutrition and Dietetics, and the American Psychiatric Nurses Association
What device and/or diagnostic marketing advances will emerge in DTC, and how should such companies experiment with media?
Consumer demand was a key drive of Pfizer's push into mobile
Havas has hired a longtime WebMD exec to lead Havas Life New York.
News on Healthline, MarketsandMarkets, Merck Serono, GSW and Trinity Pharma
Dendreon is readying a $5 million-per-quarter "targeted" DTC advertising campaign for Provenge.
The new campaign for Lilly's low testosterone treatment, Axiron, is a classic in both form and execution.
Paula Deen is making the media rounds again, and this time she has a tale of weight loss to tell.
Healthcare data and analytics giant IMS Health bought Seattle-based software-as-a-service (SaaS) company Appature.
New York University is forming a Center for Data Science, plus a master's-level degree program to prepare the next generation of data professionals
McCann HumanCare is adding to its presence in Hispanic and multicultural marketing through a partnership with sister agency Casanova Pendrill dubbed HumanCareHSP.
Medical agency Wishbone was acquired years ago, but its leadership team is coming out of retirement with a new venture, dubbed Calcium.
News on Saatchi & Saatchi Wellness, Republica and Havas Health
People in the industry must be worried about the type of care doctors are now giving
FDA commissioner Margaret Hamburg is urging the pharmaceutical industry to improve manufacturing quality
The idea of scaling back premarket clinical trials comes under fire
Provider messaging that happens near the point of care has many potential benefits
Companies have moved to bring nearly every aspect of drug marketing to mobile platforms
When a solution to a manageable condition is combined with an inspirational consumer insight, healthcare marketing can deliver a laugh along with an indelible message
Raymond Hill, President, inVentiv Clinical
At Work With
Doug Jordan, EVP, managing director, Mosaic Managed Markets
Manufacturer, agency and research promotions and hires
Apple picked up on what customers truly wanted, a more holistic experience
Skill Sets (advertising section)
What does going "beyond the pill" actually mean? At MM&M's recent inaugural spring conference, audience members heard from real-world companies that are managing the organizational, technological, and promotional challenges inherent in this transition, such as partnering with health neophytes, harnessing technologies that allow deeper engagement with patients, and adopting a new commercial mindset to serve, not sell. Download here.
A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.